High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume 23, Issue 5, Pages 675-685
Publisher
SAGE Publications
Online
2016-08-02
DOI
10.1177/1352458516661048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders
- (2015) Kamilla W. Miskowiak et al. BIOLOGICAL PSYCHIATRY
- Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
- (2015) Daniel Ontaneda et al. LANCET NEUROLOGY
- Pathological mechanisms in progressive multiple sclerosis
- (2015) Don H Mahad et al. LANCET NEUROLOGY
- The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability
- (2015) C. H. Polman et al. NEUROLOGY
- Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis
- (2014) Fatemeh Najmi Varzaneh et al. ACTA NEUROLOGICA BELGICA
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Targeting erythropoietin for chronic neurodegenerative diseases
- (2013) Zhao Zhong Chong et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with neurophysiological measurements
- (2013) A. Créange et al. NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY
- Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial
- (2013) Kamilla W Miskowiak et al. NEUROPSYCHOPHARMACOLOGY
- Unknown
- (2012) Nora Hagemeyer et al. MOLECULAR MEDICINE
- Is there a deleterious effect of erythropoietin in end-stage renal disease?
- (2011) Ajay K. Singh KIDNEY INTERNATIONAL
- Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
- (2011) DW Langdon et al. Multiple Sclerosis Journal
- Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia
- (2010) T Wüstenberg et al. MOLECULAR PSYCHIATRY
- Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice
- (2009) Michael Thorne et al. JOURNAL OF NEUROIMMUNOLOGY
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
- (2009) Hannelore Ehrenreich et al. STROKE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started